Apolipoprotein A-1 in the treatment of acute myocardial infarction

With the gradual rejuvenation and rising popularity of acute myocardial infarction, more and more researchers have begun to investigate novel treatments for this disease. The treatment plan for continuing to increase high-density cholesterol based on apolipoprotein A-1 is gradually recognized by more and more people because of its theoretical and clinical practicability. However, there are relatively fewer experiments demonstrating the viability of apolipoprotein A-1 in clinical treatment compared to aspirin or other mature technologies. This review will state the important clinical trials of apolipoprotein A-1 in treating acute myocardial infarction in recent decades, summarize its clinical information, and analyze its proof of the feasibility for apolipoprotein therapy.